VistaGen Therapeutics Inc (VTGN) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $0.60
• Market Cap: $23.03M
• EPS: $-1.90
• 52-Week High: $5.14
• 52-Week Low: $0.43

Market Sentiment

VistaGen Therapeutics Inc currently has a Bearish sentiment score of -0.62.

About VistaGen Therapeutics Inc

VistaGen Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for anxiety, depression, and other central nervous system disorders. Based in South San Francisco, California, the company is advancing its proprietary drug candidates, notably AV-101, aimed at fulfilling significant unmet needs in the mental health sector. With a strong focus on neuropharmacology and a promising pipeline, VistaGen is positioned as a key player in the rapidly ...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for VistaGen Therapeutics Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does VTGN pay dividends?

VistaGen Therapeutics Inc (VTGN) does not currently pay a regular dividend.

What is VTGN's market cap?

VistaGen Therapeutics Inc (VTGN) has a market capitalization of $23.03M with a current stock price of $0.60.